Abstract The occurrence of vitiligo in patients with melanoma is especially reported for patients undergoing immunotherapy. While vitiligo in these patients is thought to be related to an immune response directed against melanoma cells, solid evidence is lacking. Here we report local cytotoxic T cell reactivity in three melanoma patients who developed vitiligo, after experimental immunotherapy using dendritic cell vaccinations. Tetramer analysis showed that vaccine-induced T cells recognizing gp100 and tyrosinase are present at the vitiligo lesions. These T cells secrete IFN-and IL-2 upon peptide speciWc stimulation as well as upon recognition of the autologous tumor. We show that functional CD8 + T cells speciWc for melanoma diVerentiation antigens used in a melanoma immunotherapy trial, do not only invade the tumor, but also the vitiligo lesions. This directly links vitiligo to the immuno-therapeutic intervention and supports the hypothesis that vitiligo is a marker of immunity against melanoma cells.
Introduction
Vitiligo is a common skin disease that is characterized by depigmented lesions associated with local destruction of melanocytes [12] . For melanoma patients the chance to develop vitiligo is estimated to be seven to tenfold higher compared to the general population [22] , especially when they participate in an immunotherapeutic trial [25] . Based on numerous observations, development of de novo vitiligo lesions in melanoma patients is generally regarded as a favourable prognostic factor.
The etiology of vitiligo is not yet completely understood, but several lines of evidence suggest that both spontaneous and immunotherapy-associated vitiligo are immune-mediated processes. In spontaneous vitiligo, circulating anti-melanocytic antibodies and lymphocyte inWltrations at the margins of progressive lesions are present [9, 17] . Furthermore, spontaneous vitiligo is correlated with circulating cytotoxic T lymphocytes (CTLs) speciWc for melanoma diVerentiation antigens (MDAs) [19] . Analysis of vitiligo inWltrating lymphocytes (VILs) isolated from vitiligo lesions showed a local enrichment of predominantly Melan-A speciWc T cells [11, 16, 30] .
Numerous melanoma antigens are shared by normal melanocytes; amongst these are MDAs such as Melan-A/ MART-1, gp100, tyrosinase and tyrosinase related proteins [3, 7] . In two murine melanoma models, it is shown that de novo development of vitiligo is associated with reduced tumor progression. In both models, MDA-speciWc CTLs play a crucial role in both tumor control and melanomaassociated vitiligo [13, 18] . Also in humans the appearance of vitiligo during the course of melanoma is thought to be caused by a cross-reactive immune response directed against melanoma cells, which explains the better prognosis in these patients reported in literature [4, 29] .
Here we describe three melanoma patients who developed vitiligo after immunotherapeutic intervention. Patients were vaccinated with autologous monocyte-derived dendritic cells (DCs) loaded with gp100 and tyrosinase epitopes [5] . We demonstrate that CTLs against these epitopes can be detected in low percentages in the peripheral blood after vaccination. Interestingly, functional CTLs with the same speciWcity were observed in high percentages in both tumor and vitiligo lesions, which supports the hypothesis that the vitiligo is a direct cross-reactive eVect of the antimelanoma immunotherapy.
Material and methods

Patient selection
Melanoma patients with regional lymph node and distant metastases, participated in an experimental study using autologous monocyte-derived DCs loaded with HLA-A2.1 compatible tumor antigens gp100 and tyrosinase [5] . Only patients who developed vitiligo after immunotherapy, clinically conWrmed by a dermatologist, were selected. Blood samples and 6 mm biopsies of perilesional vitiligo were obtained after informed consent. Approval from the local regulatory committee was obtained.
Preparation of vitiligo-inWltrating lymphocytes (VILs)
Six mm punch biopsies of the perilesional vitiligo-site (Fig. 1a) were obtained and cut in half. One part was cryopreserved for immunohistochemistry at a later timepoint, Preparation of tumor-inWltrating lymphocytes (TILs) and melanoma cell lines
TILs were obtained and cultured according to the same protocol as the vitiligo cell suspension (see above). A tumor cell line was generated by tumor culture in DMEM (Gibco-Invitrogen) supplemented with 10% fetal calf serum (Greiner). Fresh medium was added twice a week.
MHC Tetramer staining
VILs and TILs (50 £ 10 3 cells in 10 l) or 1 £ 10 6 peripheral blood mononuclear cells in 10 l, were incubated with directly labeled gp100 [154] [155] [156] [157] [158] [159] [160] [161] [162] , gp100 [280] [281] [282] [283] [284] [285] [286] [287] [288] , tryrosinase [369] [370] [371] [372] [373] [374] [375] [376] and Melan-A 26-35 and HIV 77-85 tetrameric-MHC-HLA-A2.1 complexes for 60 min at room temperature. FITCconjugated monoclonal antibodies directed against CD8 (Becton Dickinson) were added during the last 20 min. After washing, the samples were analyzed by Xow cytometry. Percentage tetramer positive cells were calculated over the CD8 + fraction. All samples were tested with HIV 77-85 -HLA-A2.1-tetramers recognizing the irrelevant HIV-peptide SLYNTVATL as background control [5] . Control tetramer binding was less than 0.02% in all samples (supplementary Wgure 1).
Cytokine production
Production of cytokines by VILs and TILs were measured in response to speciWc stimuli (target:eVector-ratio 1:1). Two diVerent target cells were used: T2 cells pulsed with gp100
154-162 , gp100 280-288 , tryrosinase 369-376 or the irrelevant peptide HIV 77-85 and BLM cells (a melanoma cell line expressing HLA-A2.1 and no endogenous expression of gp100 and tyrosinase) transfected with control antigen G250, gp100 or tyrosinase. IFN-and IL-2 production were measured in supernatants after 16 hours by cytometric bead array according to the manufacturers protocol (Th1/Th2 Cytokine CBA 1; BD Pharmingen).
Antibodies and immunostaining
Regulatory T cell phenotype was assessed by Xowcytometry using mAbs directly conjugated to Xuorescent dyes. The FOXP3-FITC (clone PCH101, eBioscience, San Diago, CA, USA), CD4-APC, CD25-PE, CD127-PE-Cy5 (all Becton Dickinson) were used according to manufacturers protocols. Regulatory T cells were deWned as CD4
¡ . For immunohistochemistry, the following mAbs were used: M2-7C10+M2-9E3 (Labvision, Fremont, CA, USA) against Melan-A, SP7 (Labvision) against CD3, HMB-45 (Dako, Glostrup, Denmark) against gp100 and T311 (Novocastra, Newcastle, UK) against tyrosinase [6] .
Results and discussion
Patients
We prospectively followed three HLA-A2.1 positive patients with histologically documented melanoma who received DC-based immunotherapy and subsequently developed vitiligo (Table 1) .
Patient 1. Patient 1 was diagnosed, two years prior to inclusion, with melanoma of the scalp with regional lymph node metastases (T3aN2aM0), for which a radical lymph node dissection was performed. She relapsed with regional lymph node and cutaneous metastases, which were resected and treated with adjuvant radiotherapy. At inclusion, this patient presented with multiple subcutaneous and lung metastases. The patient was vaccinated intranodally with antigen loaded mature DCs [5] but treatment was discontinued after 3 vaccinations because of progression of cutaneous metastases. She developed vitiligo in the Xank during further tumor progression.
Patient 2. Patient 2 was diagnosed, twelve years prior to inclusion, with melanoma located on the right lower leg (T1aN0M0), which was surgically removed. From 1997 on, the patient relapsed with in transit and distant cutaneous metastases, for which he was treated with regional limb perfusion (melfalan) and dacarbazine. At inclusion, he was diagnosed with lymph node metastases and multiple (sub-)cutaneous metastases for which he was repeatedly vaccinated intranodally with antigen loaded mature DCs. After three vaccinations, the patient developed vitiligo in the neck region and dorsal side of both hands. To date, the vitiligo still progresses and aVects the head, back, hands and legs.
Patient 3. Patient 3 was diagnosed, 6 months prior to inclusion, with a superWcial spreading melanoma of the left thigh (T1a/bN0M0). At inclusion she presented with an inguinal lymph node metastasis, for which a radical lymph node dissection was performed. She was vaccinated intradermally in an adjuvant setting with antigen loaded mature DCs. After eight vaccinations, she developed a severe rash in the neck region, thorax, back and upper extremities and subsequent vitiligo in these areas. Vitiligo development in melanoma patients upon vaccination with DCs has been reported before [15, 24] . Although not investigated, it is currently believed that the vitiligo in these patients results from sensitization to antigens shared by melanocytes and melanoma cells. To address this question we took perilesional biopsies and studied the vitiligo inWltrating immune cells.
Vaccine speciWc lymphocytes inWltrate vitiligo lesions
Immunohistochemical analysis of the vitiligo in all three patients demonstrates perilesional inWltration of T cells (Fig. 1a, b) . With tetramer analysis, CD8 + T cells speciWc for one or more gp100 and tyrosinase HLA-A2.1 epitopes were detected at low frequencies in the peripheral blood after vaccination in all three patients. Gp100 or tyrosinase speciWc CD8 + T cells were not detectable prior to vaccination (data not shown). Interestingly, speciWc CTLs were detected at increased concentrations in the vitiligo lesion compared to peripheral blood (Table 1; supplementary Wgure 1). This phenomenon was most obvious in patient 3 (Fig. 1c, d ). The accumulation of these CTLs in the vitiligo lesions can result from speciWc migration [26] and/or a local proliferation advantage for MDA speciWc CTLs induced by perilesional antigen exposure.
Although the immunotherapy was not primarily directed against the Melan-A epitope, Melan-A speciWc CTLs were observed in the vitiligo lesions and tumor lesion of patient 1 and 2 (Table 1; Fig. 3 ). This Wnding is consistent with the observation that anti-tumor vaccines can have eVects beyond their intrinsic speciWcity. It is shown that the interaction of vaccine speciWc T cells with melanoma cells may trigger a broad activation of other anti-tumor T cells, a phenomenon called epitope spreading [10, 14] .
Vitiligo inWltrating lymphocytes produce IFNafter speciWc stimulation
To test whether vitiligo inWltrating lymphocytes (VILs) were functional, we stimulated these cells with gp100 or tyrosinase expressing target cells and measured subsequent IFN-and IL-2 production. VILs of patients 1 and 3 produce IFN-and IL-2 when exposed to gp100-target cells and VILs of patient 2 produce IFN-and IL-2 when exposed to both gp100 and tyrosinase-target cells. No cytokines were produced when VILs were exposed to unloaded control target cells (Fig. 2) .
From patients 1 and 2 we were able to culture melanoma cell lines from metastases. Interestingly, the VILs also produced IFN-and IL-2 when stimulated by the autologous tumor cell line (Fig. 2) . The cross reactivity of the VILs with autologous tumor cells further supports the hypothesis that the vitiligo is a marker of immunity against melanoma cells.
Vitiligo lesions in our patients did not speciWcally occur at the vaccine injection-site, at the site of the primary tumor, or in close proximity of new metastases. From this we conclude that the melanoma-associated vitiligo is not caused by a direct and local side-eVect of tumor destruction, but rather by the presence of circulating MDA-speciWc CTLs. Although we did not use MHC class II peptides in our vaccination protocol, our data do not exclude that speciWc CD4 + cells are involved. MDA-speciWc epitopes recognized by CD4 + T cells have been reported [31] and it is also known that melanocytes can present peptides in an MHC class II restricted manner [28] . These observations suggest that melanocyte destruction may not only depend on MHC class I-restricted cells.
Immunotherapy-associated vitiligo and prognosis
Our case series is too limited to aVord decisive conclusions on the prognostic value of vitiligo on melanoma disease. The presence of durable non-progressive disease in patients 2 and 3 suggest that the immunotherapy induced vitiligo lesions are a favourable prognostic factor. We further show that all three patients have a relatively high number of MDA-speciWc T cells in the blood, DTH biopsies and melanoma. Earlier papers have described a correlation with the presence of MDA-speciWc T cells in these compartments and favourable outcome [2, 5] . Despite the presence of functional melanoma speciWc T cells, patient 1 had progressive disease. This is intriguing since the tumor expressed the MDAs gp100 and Melan-A (IHC, Fig. 3a, b) and was inWltrated by CTLs that speciWcally recognize these epitopes (inserts Fig. 3a, b ; Table 1 ). Several mechanisms may account for the escape of melanoma cells to immune surveillance [21] . It has recently been published that CD4 + FoxP3 + CD25 + regulatory T cells (Tregs) can inWltrate melanoma tumors and locally suppress cytotoxic anti-tumor responses, also in vaccinated melanoma patients [1] . InWltration of melanoma tumors with Tregs correlates with poor prognosis [27] . In the melanoma metastasis of patient 1, we detected that 27% of the tumor inWltrating CD4 + T cells consisted of CD4 + FoxP3 + CD25 + CD127 -Tregs vs 4% of Tregs in the blood of this patient (data not shown).
Altogether, our data support an association between vitiligo and favourable outcome. However, active vaccineinduced vitiligo does not exclude tumor progression. The dichotomy between MDA-speciWc CTL responses in melanoma and vitiligo might result from quantitative CTL diVerences, the quality of the CTLs such as T cell receptor aYnity and cytokine production [20] , the amount of antigen presented [8, 23] and the diVerent environmental conditions in which these T cells exert their function [21] .
Concluding remarks
Melanoma-associated vitiligo is more often seen in patients who undergo immunotherapy. We demonstrate that immunotherapy against gp100 and tyrosinase antigens can induce speciWc and functional CTLs that invade both melanoma and vitiligo lesions. This directly links the occurrence of vitiligo to the immuno-therapeutic intervention. -epitope tetramers (vertical axis) showing 0.32% gp100 (a) and 1.7% Melan-A (b) speciWc CTLs (see also Table 1) 
